Unicycive Therapeutics Inc (UNCY) concluded trading on Wednesday at a closing price of $0.63, with 8.3 million shares of worth about $5.23 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.51% during that period and on June 11, 2025 the price saw a gain of about 18.38%. Currently the company’s common shares owned by public are about 119.75M shares, out of which, 100.03M shares are available for trading.
Stock saw a price change of -18.72% in past 5 days and over the past one month there was a price change of 11.39%. Year-to-date (YTD), UNCY shares are showing a performance of -20.69% which decreased to -18.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $1.10 during that period. The average intraday trading volume for Unicycive Therapeutics Inc shares is 2.41 million. The stock is currently trading -1.14% below its 20-day simple moving average (SMA20), while that difference is up 3.28% for SMA50 and it goes to 12.01% higher than SMA200.
Unicycive Therapeutics Inc (NASDAQ: UNCY) currently have 119.75M outstanding shares and institutions hold larger chunk of about 50.74% of that.
The stock has a current market capitalization of $75.98M and its 3Y-monthly beta is at 1.98. It has posted earnings per share of -$0.20 in the same period. It has Quick Ratio of 1.64 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for UNCY, volatility over the week remained 32.98% while standing at 14.44% over the month.
Stock’s fiscal year EPS is expected to rise by 70.74% while it is estimated to increase by 1070.24% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Guggenheim on April 21, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Piper Sandler stated Unicycive Therapeutics Inc (UNCY) stock as an Overweight in their note to investors on April 04, 2024, suggesting a price target of $9 for the stock.
